Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 10/4/15  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Michael L. Kranda

Wrong Michael L. Kranda?

Chairman At Cardero Therapeutics

Vulcan Capital
Phone: (425) ***-****  
Vulcan Inc.
505 Fith Ave. S Suite 900
Seattle , Washington 98104
United States

Company Description: Vulcan Ventures Inc. of Seattle was founded by investor Paul G. Allen in 1986 to research and implement his investments. Through Vulcan Ventures, Allen invests in...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • BA
    University of Washington School of Business
  • BA , finance
    University of Washington
  • M.D.
  • MBA
  • MBA
    University of Washington School of Business
176 Total References
Web References
Raven Biotechnologies inc. Raises $48.3 Million in Series D Financing
www.vcgate.com [cached]
The company also announced that Michael Kranda, Managing Director at Vulcan Capital, has joined Raven's board of directors. Prior to Vulcan, Mr. Kranda was COO at Immunex (now Amgen) Corporation. Montgomery & Co.
...
"We believe RAV12 has the potential to be a promising new therapy for GI cancers that affect millions of patients," said Michael Kranda, Managing Director at Vulcan Capital and new board member of Raven.
Team | BEAT BioTherapeutics
beatbiotherapeutics.com [cached]
Michael Kranda, MBA - Chief Executive Officer, President and Director - Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development.
...
Mr. Kranda started his biotech career at Immunex Corporation where he served as President, COO and Director and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT).
...
Michael Kranda - Chief Executive Officer and President.
BEATBio Board of Directors | BEAT BioTherapeutics
beatbiotherapeutics.com [cached]
Michael Kranda | Chief Executive Officer
Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO and a director of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital (Paul Allen's investment vehicle) for several years, where he led all aspects of their Life Sciences investment efforts and continues to serve as a consultant. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development.
...
Prior to joining Oxford GlycoSciences, Mr. Kranda was President, COO and director at Immunex Corporation (now Amgen) and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT) and Chairman of the Audit Committee.
BEATBio Leadership | BEAT BioTherapeutics
beatbiotherapeutics.com [cached]
Michael Kranda, MBA - Chief Executive Officer - Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development.
...
Mr. Kranda started his biotech career at Immunex Corporation where he served as President, COO and Director and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT).
...
Michael Kranda - Chief Executive Officer.
University Technology and Start-up Gap Funding - Beat Biotherapeutics, A U Washington Start-up, Raises $2.5M For Heart Failure Treatment
www.gapfunding.org [cached]
The announcement comes a week after Beat said it hired Michael Kranda to be its new CEO. Kranda was formerly the CEO of Oxford Glycosciences, and managing director of Vulcan Capital's life sciences portfolio.
...
Kranda has been a well-known player in Seattle's biotech community dating back to the 1980s when he was the chief operating officer of Immunex.
...
Michael Kranda, CEO of Beat Biotherapeutics
...
"This financing is an important milestone for BEATBio and will allow us to move rapidly forward with the development of our lead product," Kranda said in a statement.
Other People with the name "Kranda":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304